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Abstract
Huntington’s disease (HD) is a neurodegenerative disorder for which there are no disease-
modifying treatments. SIRT1 is a NAD+-dependent protein deacetylase that is implicated in
maintaining neuronal health during development, differentiation and ageing. Previous stud-
ies suggested that the modulation of SIRT1 activity is neuroprotective in HD mouse models,
however, the mechanisms controlling SIRT1 activity are unknown. We have identified a stri-
atum-specific phosphorylation-dependent regulatory mechanism of SIRT1 induction under
normal physiological conditions, which is impaired in HD. We demonstrate that SIRT1 activ-
ity is down-regulated in the brains of two complementary HD mouse models, which corre-
lated with altered SIRT1 phosphorylation levels. This SIRT1 impairment could not be
rescued by the ablation of DBC1, a negative regulator of SIRT1, but was linked to changes
in the sub-cellular distribution of AMPK-α1, a positive regulator of SIRT1 function. This work
provides insights into the regulation of SIRT1 activity with the potential for the development
of novel therapeutic strategies.
Introduction
Huntington's disease (HD) is a devastating neurodegenerative disorder caused by a CAG repeat
expansion within exon 1 of the huntingtin gene (HTT), which encodes for an expanded polyglu-
tamine (polyQ) tract in the huntingtin protein (HTT) [1]. Symptoms usually appear in mid-life,
comprise personality changes, problems with motor coordination and cognitive decline; disease
duration lasts between 15 and 20 years and there are no disease-modifying treatments [2]. The
neuropathology of HD is characterised by neuronal cell death in the striatum, cortex and other
brain regions and the accumulation of cytoplasmic and nuclear aggregates [3].
Mouse models of HD include those that are transgenic for N-terminal fragments of HTT
(e.g. R6/2) or the full length HTT protein or are knock-in models in which the HDmutation
has been introduced into mouse Htt (e.g. HdhQ150) [4]. The R6/2 mouse is transgenic for an
exon 1 HTT protein [5] and is a model of the aberrant splicing that occurs in HD [6]. The
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HdhQ150 model had a 150 CAG repeat knocked into the mouse Htt gene [7]. In addition to
the full length protein, HdhQ150 mice express mutant exon 1 HTT through aberrant splicing
[6] and many other N-terminal HTT fragments generated through proteolysis [8]. At late stage
disease (14 weeks for R6/2 and 22 months for homozygous HdhQ150 mice) these models
exhibit remarkably similar phenotypes [9–14] the main difference between these two models
being the age of disease onset and rate of disease progression.
SIRT1, a mammalian orthologue of the yeast Sir2 protein, is a NAD+-dependent deacetylase
that plays a critical role in multiple biological processes including apoptosis [15], ageing [16],
metabolism [17] and various stress responses [18]. It has been demonstrated that DBC1
(deleted in breast cancer 1) inhibits SIRT1 via a direct interaction with its catalytic domain
[19]. This dynamic interaction is sensitive to the energetic state of the cell and involves the
activity of AMPK (AMP-activated protein kinase), an important cellular energy sensor [20]. In
circumstances of low cellular energy, AMPK stimulates compensatory processes, including the
activation of SIRT1, resulting in the restoration of ATP levels [21]. However, the complexity of
SIRT1 functions in the mammalian brain and the mechanisms involved in SIRT1 regulation
are not fully understood.
SIRT1 has been shown to participate in neuronal protection and survival in various mouse
models of neurodegenerative disorders through a number of substrates such as P53 [22] and
HSF1 [23]. With relevance to HD, the activation of Sir2 was protective against mutant pheno-
types in a C. elegansmodel [24]. Increased expression of Sirt1 attenuated neurodegeneration
and improved motor function in N171-82Q and BACHDmice [25] and attenuated brain atro-
phy and reduced mutant HTT aggregation in R6/2 mice without prolonging lifespan [26].
More recently, SRT2104, a SIRT1 activator was reported to have beneficial effects in an HD
mouse model [27] with the potential for interrogating SIRT1 activity in the clinic [28]. In con-
trast, a SIRT1 inhibitor, selisistat, has been reported to alleviate HD-related phenotypes in mul-
tiple HDmodels [29] and has been found to be safe in clinical trials [30]. Based on these
findings, the mis-regulation of SIRT1 could have important implications in the development
and progression of HD.
In this study we describe a striatum-specific phosphorylation-dependent regulatory mecha-
nism that controls SIRT1 activity under normal physiological conditions that is impaired in
HD. We show that SIRT1 activity is decreased in the brains of R6/2 and HdhQ150 mice, and
that this is not caused by the sequestration of SIRT1 into HTT inclusions. We demonstrate that
the presence of mutant HTT in the striatum and cerebellum of HD mice alters the phosphory-
lation status of SIRT1 and that these effects are related to the abnormal expression and cellular
localization of AMPK-α1. Finally, we show that the ablation of DBC1, a negative regulator of
SIRT1 [31] does not rescue the deficit in SIRT1 activity in HDmouse models. These results
provide new insights into the mechanisms that regulate SIRT1 function and may lead to the
development of new strategies by which SIRT1 can be manipulated for therapeutic benefit.
Materials and Methods
Ethics
All experimental procedures performed on mice were conducted under a project licence from
the Home Office (Animal Scientific Procedures Act 1996) and approved by the King's College
London Ethical Review Process Committee.
Mouse maintenance, breeding, genotyping, and CAG repeat sizing
Hemizygous R6/2 mice [5] were bred by backcrossing R6/2 males to (CBA × C57BL/6) F1
females (B6CBAF1/OlaHsd; Harlan Olac). HdhQ150/Q150 homozygous mice [9] on a
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(CBA × C57BL/6) F1 background were generated by intercrossingHdhQ150/Q7 heterozygous
CBA/Ca and C57BL/6J congenic lines (inbred lines from Harlan Olac). R6/2 and HdhQ150/Q150
homozygous mice were genotyped and the CAG repeat was sized as previously described [32].
The mean repeat size (± SD) for all mice used in the entire study was 165 ± 10 for HdhQ150/Q150
homozygous mice and 204 ± 7 for R6/2 mice. Dbc1 heterozygous mice were obtained from the
Eduardo Chini at the Mayo Foundation, Mayo Clinic College of Medicine, Rochester, Minne-
sota, USA. PCR conditions for genotyping Dbc1 knock-out mice have been previously
described [19]. SirT1 floxed homozygous (SirT1 Fl/Fl) mice were obtained from the JAX Labo-
ratory (Mouse Strain: B6;129-SirT1tm1Ygu/J) [33] and were bred with β-actin/Cre heterozy-
gous mice to generate complete Sirt1KOmice. Sirt1 transgenic mice (CBA×C57BL/6J) [34]
were obtained from David Holzman’s laboratory at Washington University, Missouri, USA
Animals were housed under 12 h light/12 h dark cycle, with unlimited access to water and
food (Special Diet Service, Witham, UK) in a conventional Unit. Cages were environmentally
enriched with a cardboard tube. R6/2 mice and all mice in phenotypic assessment trials were
always given mash food consisting of powered chow mixed with water from 12 weeks of age
until sacrificed. Upon sacrifice, dissected brain regions, whole brains or peripheral tissues were
snap frozen in liquid nitrogen and stored at -80°C until use.
Mouse behavioural analysis
At 4 weeks of age, mice were weaned into cages of 5–6 animals. Each cage contained at least
one representative of each genotype from mixed litters. The analysis of mice of different geno-
types was distributed equally throughout the assessment period on any given day and all beha-
vioural tests were performed blind to the investigator. Mice were weighed weekly and rotarod
performance and grip strength were assessed as previously reported [35–37]. The statistical
power of these tests was calculated as previously described [37]. The data were analysed by
repeated measures general linear model ANOVA using SPSS software [37].
Protein extraction for SDS PAGE, Immunoblotting and
Immunoprecipitation
Frozen mouse brain tissue was homogenized in 1 volume of ice cold NETN buffer (20 mM
Tris-HCl pH 8, 100 mMNaCl, 1 mM EDTA, 0.5% NP-40, complete protease inhibitors and
phosphatase inhibitors) using a polytron homogenizing probe. Samples were sonicated on ice
with a vibracell sonicator (10 x 1 s 20 kHz pulses) and spun at 13,000 x g for 10 min at 4°C. The
supernatant was retained and protein concentration was determined for each sample by the
BCA assay (Thermo Scientific).
SDS PAGE and Immunoblotting
Protein lysates were diluted with 2x Leammli Buffer, denatured for 10 min at 95°C, loaded
onto SDS polyacrylamide gels and subjected to western blot as previously described [8]. Mem-
branes were blocked in 5% non-fat dried milk in PBS—0.2% Tween 20 (PBS-T) or 4% BSA for
2 h at RT. Primary antibodies were added overnight at 4°C in 5% non-fat dried milk in PBS-T
(DBC1, SIRT1, HTT, AMPK-α1,) or 4% BSA (MpM2). β-actin, ATP5B, α-tubulin and histone
pan-H3 were incubated for 20 min at RT in 5% non-fat dried milk in PBS-T. Blots were washed
three times for 10 min in 0.2% PBS-T, incubated with the appropriate secondary antibody for 1
h at RT, washed three times for 10 min in 0.2% PBS-T and exposed to ECL according to manu-
facturer’s instruction (Amersham). The signal was developed using Amersham hyperfilm and
Xenograph developer. Densitometry of western blots was performed using a Bio-Rad GS-800
densitometer. Developed films were scanned and the average pixel optical density (OD) for
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each band was measured using QuantityONE software. The OD of an area devoid of bands was
subtracted from the values obtained for bands of interest in order to normalize the OD against
background. Relative expression was determined by dividing the normalized OD of bands of
interest by the OD of the appropriate loading control for each sample. For full details of pri-
mary antibodies see S1 Table.
Immunoprecipitation
Protein lysates were prepared for immunoprecipitation (IP) as described above. For IP from
striatal lysates, striata were pooled from two animals. IP reactions were performed in 1 ml of
NETN buffer containing from 400 to 1000 μg protein and 1 μg of antibody and normal rabbit
IgG (#2729; Cell Signaling) was used as a negative control. Reactions were left on a rotating
wheel at 4°C for 90 min (AMPK-α1) or 4 h (SIRT1) and 15 μl of protein G-coupled Dynabeads
(10004D; Life Technologies) were added for the last 45 min. Following IP, protein G-coupled
Dynabeads were briefly spun at 13,000 x g for 30 sec, put on a magnetic rack, washed with 1 ml
of NETN buffer (4x) and re-suspended in 15 μl of 2x Leammli buffer. Immuno-precipitated
complexes were eluted from the beads by denaturation at 100°C for 10 min and immediately
loaded for SDS-PAGE analysis.
Nuclear/cytoplasmic fractionation
All steps were performed on ice. Half brain tissue or liver was cut into small pieces and homog-
enized with a Dounce homogenizer in TKM buffer (0.25 M sucrose; 50 mM Tris-HCl, pH 7.4;
25 mM KCl; 5 mMMgCl2 and 1 mM PMSF) and nuclear and cytoplasmic fractions were pre-
pared as previously described [19]. For the nuclear and cytoplasmic preparations from brain
regions, striata were pooled from four animals, whereas a single cerebellum was used. The final
pellet containing the purified nuclei was resuspended in 4% PFA for immunohistochemistry or
in NETN buffer for protein analysis and protein concentration was determined by the BCA
assay (Thermo Scientific).
Immunohistochemistry
The isolation of nuclei from brain or liver was as described above. Nuclei were extracted from 4
mice per genotype from half brain or liver and for brain regions, from two pools each containing
specific regions from five mice. Samples were fixed on the slide for 30 min with 4% paraformal-
dehyde prepared in PBS, permeabilized with 0.1% Triton X-100 in PBS for 15 min, washed 3X
with PBS, and incubated for 1 h at RT in blocking buffer (PBS with 0.1% Triton and 1% BSA).
Nuclei were incubated with the primary antibody in blocking buffer (DBC1, SIRT1, P53 and
Ac-P53) overnight at 4°C, washed 3x with PBS at RT and then incubated with the secondary
antibody and DAPI in PBS—0.1% Triton for 1 h at RT. Samples were mounted using VECTA-
SHIELDmounting medium. Nuclei were visualized using a TCS SP2 Leica confocal microscope.
Fluorescence intensity was quantified from 50 nuclei per sample imaged from 10 fields of view
per slide using ImageJ. Ac-P53 levels were normalised to the P53 intensity level. Fluorescent
intensity levels were presented as a fold change fromWT levels as indicated in the figures. The
direction of the fold change was inverted to depict the comparative deacetylase activity.
Fluor de Lys assay
SIRT1 activity was determined with a SIRT1 Fluorometric Kit (BML-AK555) according to the
manufacturer’s instructions. Protein extraction was performed as described above. Homoge-
nates were then incubated for 10 min at 37°C to allow degradation of any contaminant NAD+.
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10 mMDTT was added to the medium, and homogenates were incubated again for 10 min at
37°C. The homogenates (20–30 μg protein/well) were then incubated in SIRT1 assay buffer in
the presence of 50, 100 or 200 μM Fluor de Lys–SIRT1 substrate (Enzo Life Sciences), 5 μM
TSA and 200 μMNAD+. After 0-, 20-, 40- and 60 minutes of incubation at 37°C, the reaction
was terminated by adding a solution containing Fluor de Lys Developer (Enzo Life Sciences)
and 2 mM nicotinamide. After 1 h the values were determined by reading fluorescence on a
fluorometric plate reader (Spectramax Gemini XPS; Molecular Devices) with an excitation
wavelength of 360 nm and an emission wavelength of 460 nm.
Taqman RT-qPCR
RNA extraction, cDNA sysnthesis, Taqman RT-qPCR and ΔCt analysis were performed as
described previously [38]. The Taqman qPCR assays were purchased from Primer Design and
ABI. For a list of primers and probes, see S2 Table.
Statistical Analysis
Statistical analysis was performed with SPSS (repeated measures ANOVA General Linear
Model) or Microsoft Excel (Student's t-test) software. p-values of<0.05 were considered signif-
icant. Graphs were constructed using Prism Ver.5.0b (GraphPad Software).
Results
SIRT1 function becomes compromised in the brains of HD mice
There is considerable evidence to support the beneficial effect of SIRT1 manipulation in HD
mouse models. However, the impact of mutant HTT on SIRT1 function has not been fully elu-
cidated. As such, we set out to analyse SIRT1 activity and the mechanisms involved in its regu-
lation in two different mouse models of HD: R6/2 transgenic andHdhQ150 knock-in
homozygous mice.
SIRT1 regulates the activity of several transcription factors including P53 [39]. It deacety-
lates P53 on Lys382 thereby inhibiting its function [40]. There are a number of commercial kits
that use the deacetylation of this P53 lysine residue to assess SIRT 1 activity. In order to have a
direct measurement of SIRT1 activity, we applied the Fluor-de-Lys fluorometric activity assay
(Enzo Laboratories). The specificity of the kit was evaluated on lysates from the brains of
SIRT1 knock-out (Sirt1KO) [33] mice at 4 weeks of age, but unfortunately we found that this
kit was not specific for SIRT1 in these brain lysates (S1 Fig). Therefore we tested an alternative
published method to assess the steady-state levels of SIRT1 activity on endogenous P53 in
mouse brains that makes use of nuclei purified from mouse tissues [19]. The genotypes of the
mice used for the experiment were verified by western blot (Fig 1A). Nuclei were isolated from
the brains of Sirt1KO and Sirt1Tg mice [34] at 4 weeks of age and immunostained for P53 and
acetylated-P53 (AcP53) at Lys382, and counterstained with DAPI (Fig 1B). P53 levels were
equivalent between the Sirt1KO and Sirt1Tg lines and the corresponding wild type (WT) litter-
mates (Fig 1C). The acetylation of P53 Lys 382 was considerably increased in the Sirt1KO
nuclei and decreased in those from the Sirt1Tg mice, consistent with a decrease in SIRT1 activ-
ity in the knock-out line and an increase in SIRT1 activity in the transgenic line respectively
(Fig 1C), demonstrating that this approach could be used to monitor the steady-state level of
SIRT1 activity in mouse brain.
To monitor the level of SIRT1 activity in HD mouse models, we isolated cell nuclei from the
brains of R6/2 mice at 4, 9 and 14 weeks of age andHdhQ150 homozygous mice at 2 and 22
months together with their aged-matched WT littermates. Nuclei were immunostained for
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SIRT1, P53 and acetylated-P53 (AcP53), and counterstained with DAPI (Fig 2A and S2A Fig).
We did not detect any variation in the intensity level of SIRT1 and P53 staining between HD
mouse samples and their corresponding WT controls at each age of analysis (Fig 2B and S2B
Fig). In contrast, whilst we found that the acetylation levels of endogenous P53 were equivalent
in HD as compared to WT littermate brains in presymptomatic mice (i.e. 4 week R6/2 and 2
month HdhQ150 homozygotes) (Fig 2A and 2B), the level of AcP53 was significantly higher
( 1.5 fold) in samples from early symptomatic R6/2 mice (9 weeks) and late stage symptom-
atic R6/2 (14 weeks) and HdhQ150 homozygous (22 months) mice (Fig 2A and 2B and S2A
and S2B Fig), suggesting that SIRT1 activity becomes impaired in the HD mouse brain. SIRT1
activity was also found to be compromised in the livers of 14 week old R6/2 and 22 month
HdhQ150 mice (S2C, S2D, S2E and S2F Fig).
SIRT1 does not co-localize with mutant HTT inclusions and is aberrantly
phosphorylated in HD mice
Previous studies have shown that SIRT1 interacts with HTT in vitro [26]. To investigate
whether the altered SIRT1 activity is caused by the sequestration of SIRT1 into HTT inclusions,
we performed a double staining for SIRT1 and HTT (EM48) on nuclei isolated from the brains
of 14-week R6/2 and 22-monthHdhQ150 homozygous mice, together with their age-matched
WT littermates. Interestingly, SIRT1 did not co-localize with HTT inclusions (Fig 3A). To
Fig 1. Method for monitoring the steady-state levels of SIRT1 activity in mouse tissues. (A) Representative western blot for SIRT1 in half brain from
Sirt1KO and Sirt1Tg mice at 4 weeks of age. (B) Representative immunofluorescence image of isolated nuclei extracted from half brains from Sirt1KO and
Sirt1Tg mice at 4 weeks of age immunostained for P53 and AcP53 and counterstained with DAPI. (C) Relative intensity level of P53 and AcP53 from the
immunostained nuclei shown in B. The quantification indicates that the level of acetylated P53 is higher in the Sirt1KOmice, consistent with a decrease in
SIRT1 activity, and lower in Sirt1Tg mice, consistent with an increase in SIRT1 activity. Data are the mean ± SEM. ***p<0.001. Scale bar, 10 μm; KO =
Sirt1KO; Tg = Sirt1Tg. n = 4 / genotype.
doi:10.1371/journal.pone.0145425.g001
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further support this finding, the levels of SIRT1 protein were not decreased in HD brains as
judged by western blot (Fig 3B).
The role of post-translational modifications (PTMs) in the regulation of SIRT1 activity has
been the subject of several studies and phosphorylation has been described as a major control
Fig 2. SIRT1 activity becomes reduced with disease progression in HDmousemodels. (A) Representative immunofluorescence image of isolated
nuclei extracted from half brains from R6/2 mice at 4 and 9 weeks of age andHdhQ150 homozygotes at 2 and 22 months immunostained for SIRT1, P53 and
AcP53 and counterstained with DAPI. (B) Relative intensity level of SIRT1, P53 and AcP53 from the immunostained nuclei shown in A. The quantification
indicates that the level of acetylated P53 is higher in the HDmodels, consistent with a decrease in SIRT1 activity. Data are the mean ± SEM. ***p<0.001.
Scale bar, 10 μm; Hdh = HdhQ150 homozygotes. n = 4 / genotype.
doi:10.1371/journal.pone.0145425.g002
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Fig 3. SIRT1 does not co-localize with HTT inclusions and is aberrantly phosphorylated in HDmice. (A) Representative immunofluorescence image of
isolated nuclei extracted from half brains from R6/2 mice at 14 weeks of age andHdhQ150 homozygotes at 22 months immunostained for both SIRT1 and
mutant HTT (EM48), and counterstained with DAPI. (B) Representative western blot showing SIRT1 levels in half brains from R6/2 mice at 14 weeks of age
andHdhQ150 homozygotes at 22 months as compared to their WT littermates and relative quantification. (C) Western blots of SIRT1 and HTT after SIRT1
immunoprecipitation from half brain lysates of R6/2 andHdhQ150 homozygotes as compared to their WT littermates. IP = immunoprecipitation;
WB = western blotting.Hdh = HdhQ150 homozygotes. Scale bar, 10 μm.
doi:10.1371/journal.pone.0145425.g003
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mechanism [41]. Therefore, to understand how mutant HTT reduces SIRT1 activity, we moni-
tored the phosphorylation status of SIRT1 in HD mice. We performed SIRT1 immunoprecipi-
tation from the brains of R6/2 mice at 9 weeks of age andHdhQ150 homozygous mice at 22
months and probed the phosphorylation level of SIRT1 by western blot using the mitotic phos-
phoprotein monoclonal 2 (MpM2) antibody [42]. This antibody detects the phosphorylation
of serine and threonine residues when they are followed by a proline (S/T-P sites) and it is not
specific for a SIRT1 phosphorylation site (S3 Fig). Interestingly, a higher level of phosphory-
lated SIRT1 was found in the brains of both R6/2 and HdhQ150 homozygotes as compared to
their WT littermates (Fig 3C). As previously shown in vitro [26], we were able to co-immu-
noprecipitate endogenous HTT from R6/2 lysates and mutant HTT andWT HTT from
HdhQ150 homozygous andWT lysates respectively (Fig 3C). These results suggest that the
impairment in SIRT1 function in the brains of HD mice is not related to its sequestration into
HTT inclusions, but rather to an alteration in its phosphorylation profile.
SIRT1 phosphorylation becomes decreased in the striatum and
increased in the cerebellum of HDmice
The analysis of total brain samples might mask or dilute any regional pathological changes.
Therefore, we extended the analysis of SIRT1 phosphorylation to the striatum, cortex and cere-
bellum of R6/2 mice at 4, 9, and 14 weeks of age. We did not detect any difference in the phos-
phorylation status of SIRT1 at presymptomatic stages of the disease (i.e. 4-week-old R6/2) as
compared to WT littermates in any brain region (Fig 4A and 4C and S4 Fig). In keeping with
our functional data from total brain, the levels of phosphorylated SIRT1 were altered in the
striatum and cerebellum of R6/2 mice by 9 weeks of age (Fig 4A and 4C). Surprisingly, the level
of phosphorylation of SIRT1 remained unchanged in the R6/2 cortex at these later stages (S4
Fig), but notably was decreased in the striatum (Fig 4A) and increased in the cerebellum (Fig
4C) as compared to WT littermates. These data were replicated in the HdhQ150 homozygous
mice: there was no difference in the SIRT1 phosphorylation level at 2 months of age (Fig 4B
and 4D) whereas SIRT1 phosphorylation was decreased in the striatum and increased in the
cerebellum of 22-month-old HdhQ150 homozygous mice (Fig 4B and 4D). Taken together,
these results demonstrate that the presence of mutant HTT alters the phosphorylation status of
SIRT1 in opposing directions for the striatum and cerebellum as the disease progresses.
Induction of SIRT1 activity is blocked in the striatum
Phosphorylation plays a central role in controlling protein activity, cellular localization and
degradation [43]. To determine whether the differentially altered phosphorylation profile of
SIRT1 in striatum and cerebellum corresponded to a compromised SIRT1 function in these
brain regions, we immunostained for SIRT1, P53 and AcP53 in nuclei from the striatum and
cerebellum of R6/2 and WTmice at 4, 9 and 14 weeks of age. Consistent with the total brain
data, we did not detect a change in the intensity level of SIRT1 and P53 staining in either the
striatum or cerebellum of R6/2 andWT mice, at any of the ages studied (S5A and S5B, S6A
and S6B Figs). Interestingly, we observed a significant reduction in the level of AcP53 in the
striatum of WT mice, corresponding to an increase in SIRT1 activity, between 4 and 9 weeks of
age, which was absent in the striatum of R6/2 mice (Fig 5A and 5B). In contrast, when we ana-
lysed SIRT1 activity in the cerebellum, we detected no change in the level of AcP53 in WT sam-
ples at these ages and there was a significant increase in AcP53 in the cerebellum of R6/2 mice
from 4 to 14 weeks of age (Fig 5C and 5D), corresponding to an impairment in SIRT1 activity.
These data highlight that SIRT1 activity is regulated by different mechanisms in the striatum
and cerebellum of WT mice between 4 and 14 weeks of age; SIRT1 activity is induced in the
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striatum between 4 and 9 weeks, whereas it remains constant in the cerebellum. The presence
of mutant HTT can block this induction process in the striatum and cause a reduction in nor-
mal SIRT1 function in the cerebellum resulting in an impairment of SIRT1 activity in both
brain regions (Fig 5).
SIRT1 induction in the striatum correlates with age-dependent
phosphorylation
The comparison of SIRT1 activity in the striatum and cerebellum revealed that SIRT1 function is
controlled by different mechanisms in these two brain regions inWTmice. In the striatum, SIRT1
is activated with age, a process that does not occur in the cerebellum. To monitor changes in the
phosphorylation status of SIRT1 under normal physiological conditions we immunoprecipitated
Fig 4. SIRT1 phosphorylation is altered in HDmousemodels. (A, B) Western blots of SIRT1 and phosphorylated SIRT1 (MpM2) after SIRT1
immunoprecipitation from the striatum of R6/2 mice at 4, 9 and 14 weeks of age andHdhQ150 homozygotes at 2 and 22 months as compared to their WT
littermates. (C, D) Western blots of SIRT1 and phosphorylated SIRT1 (MpM2) after SIRT1 immunoprecipitation from the cerebellum of R6/2 mice at 4, 9 and
14 weeks of age andHdhQ150 homozygotes at 2 and 22 months as compared to their WT littermates. IP = immunoprecipitation, WB = western blotting.Hdh
= HdhQ150 homozygotes. Data are representative of at least three independent experiments.
doi:10.1371/journal.pone.0145425.g004
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Fig 5. The induction of SIRT1 activity is blocked in the striatum in R6/2 mice. (A) Representative immunofluorescence images of isolated nuclei
extracted from the striata of WT and R6/2 mice at 4, 9 and 14 weeks of age immunostained for AcP53 and counterstained with DAPI. (B) The relative
fluorescent intensity level of AcP53 indicates that the level of acetylated P53 is lower in the striatum of WTmice as compared to the HDmodel, consistent
with an increase in WT SIRT1 activity. (C) Representative immunofluorescence images of isolated nuclei extracted from the cerebella of WT and R6/2 mice
at 4, 9 and 14 weeks of age immunostained for AcP53 and counterstained with DAPI. (D) The relative fluorescent intensity level of AcP53 indicates that the
level of acetylated P53 is higher in the cerebellum of HD models, as compared to WT, consistent with a decrease in SIRT1 activity. Scale bar, 10 μm. Data
are the mean ± SEM. ***P<0.001: statistically significant difference compared to 4 weekWT. ###P<0.001: statistically significant difference between R6/2
andWT. n = 4 / genotype.
doi:10.1371/journal.pone.0145425.g005
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SIRT1 from striatal and cerebellar lysates ofWTmice at 4, 9 and 14 weeks and immunoprobed
with the MpM2 antibody. Notably, SIRT1 phosphorylation levels decreased in the striatum
between 4 and 9 weeks of age (Fig 6A), a time at which the functional data revealed an increase in
SIRT1 activity (Fig 5A and 5B). However, it then dramatically increased at 14 weeks (Fig 6A), a
stage at which SIRT1 activity remains constant as compared to 9 weeks (Fig 5A and 5B). The
MpM2 antibody detects phosphorylation on serine and threonine residues followed by proline (S/
T-P sites) and is not specific for a SIRT1 phosphorylation site; therefore, the increased phosphory-
lation signal at 14 weeks may correspond to the phosphorylation of different SIRT1 residues to
those detected a 4 and 9 weeks of age. Conversely, SIRT1 activity remains constant during these
ages in the cerebellum (Fig 5C and 5D) and this is reflected by a phosphorylation level that does
not change (Fig 6B). Taken together these data provide a link between the phosphorylation status
of SIRT1 and its function, suggesting that in the striatum changes in the SIRT1 phosphorylation
with age might be related to the induction of SIRT1 activity.
The sub-cellular distribution of SIRT1 is not altered in R6/2 mice
Previous studies suggested that the phosphorylation of human SIRT1 can increase its nuclear
localization and enzymatic activity [44]. To assess whether the mis-regulation of SIRT1 phos-
phorylation could affect its nuclear localization we prepared nuclear and cytoplasmic fractions
from the striatum and cerebellum of R6/2 andWT mice at 9 and 14 weeks of age. Notably, we
did not detect any difference in the distribution of SIRT1 at these ages between R6/2 andWT
mice in either brain region (Fig 7A and 7B). However, the level of SIRT1 in the nuclear fraction
was more pronounced at 14 weeks as compared to 9 weeks of age in the striatum and cerebel-
lum of both R6/2 andWT mice (Fig 7A and 7B). We went on to analyse the phosphorylation
level of SIRT1 in these two cellular compartments from the cerebellum by immunoprecipita-
tion. This was not possible from the striatum due to limiting quantities of the extracts. Interest-
ingly, a strong phosphorylation signal was detected in the nuclear fraction, that was absent
Fig 6. The striatum-specific regulatory mechanism of SIRT1 activity in HDmice is age-dependent.
Western blots of SIRT1 and phosphorylated SIRT1 (MpM2) after SIRT1 immunoprecipitation from (A) the
striatum of WTmice at 4, 9 and 14 weeks, and from (B) the cerebellum of WTmice at 4, 9 and 14 weeks;
IP = immunoprecipitation; WB = western blot.
doi:10.1371/journal.pone.0145425.g006
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from the cytoplasm, for both R6/2 and WT samples and, as previously shown on total lysates,
the level of phosphorylation was much higher in R6/2 as compared to WT mice (Fig 7C).
These results demonstrate that the sub-cellular distribution of SIRT1 is not affected by the
presence of mutant HTT and suggests, once again, that the phosphorylation levels might be
directly linked to the regulation of SIRT1 activity.
Tissue specific alteration of the subcellular distribution of AMPK-α1 with
disease progression
Previous studies showed that DBC1 directly interacts with the catalytic domain of SIRT1 inhib-
iting its activity both in vitro and in vivo [19]. This dynamic interaction is sensitive to the ener-
getic state of the cell [19]. Activation of AMP-activated protein kinase-α1 (AMPK-α1), an
important energy sensor in circumstances of low cellular energy, was recently shown to induce
the activation of SIRT1 through the dissociation of SIRT1 and DBC1 [20,45]. To identify the
possible role of AMPK-α1 and DBC1 in the molecular phenotypes described so far, we decided
to study the interaction between these two opposing modulators of SIRT1 using co-immuno-
precipitation. We immunoprecipitated AMPK-α1 from the striatum and cerebellum of 9-week
R6/2, 22-month HdhQ150 homozygous andWT littermates and detected the co-immunopre-
cipitated DBC1. Interestingly, we observed a stronger interaction between AMPK-α1 and
DBC1 in the striatum of HD as compared to WT mice (Fig 8A), whereas equivalent amounts
Fig 7. The sub-cellular distribution of SIRT1 is not altered in R6/2 mice. (A) Western blot for nuclear (N) and cytoplasmic (C) extracts from the striatum of
R6/2 andWTmice at 9 weeks and 14 weeks of age immunoprobed with SIRT1, α-tubulin and histone H3. (B) Western blot for nuclear (N) and cytoplasmic
(C) extracts from the cerebellum of R6/2 andWTmice at 9 weeks and 14 weeks of age immunoprobed with SIRT1, α-tubulin and histone H3. (C) Western
blot of SIRT1 and phosphorylated SIRT1 (MpM2) after SIRT1 immunoprecipitation from nuclear and cytoplasmic fractions extracted from the cerebellum of
R6/2 andWTmice at 9 weeks of age. IP = immunoprecipitation; WB = western blot.
doi:10.1371/journal.pone.0145425.g007
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Fig 8. The DBC1-AMPK-α1 interaction is increased in the striatum of HDmice. (A-B) Western blots of DBC1 and AMPK-α1 after AMPK-α1
immunoprecipitation from (A) the striatum of 9-week R6/2 and 22-monthHdhQ150 homozygotes, and (B) the cerebellum of 9-week R6/2 and 22-month
HdhQ150 homozygotes. (C-D) Western blot for DBC1, AMPK-α1, α-tubulin and histone H3 of nuclear (N) and cytoplasmic (C) extracts from (C) striatum and
(D) cerebellum of WT and R6/2 mice at 9 and 14 weeks of age. (E-F) Representative immunofluorescence image of nuclei extracted from (E) striatum and (F)
cerebellum of WT and R6/2 mice at 4, 9 and 14 weeks of age immunostained for AMPK-α1 and counterstained with DAPI. Scale bar, 10 μm.
IP = immunoprecipitation.
doi:10.1371/journal.pone.0145425.g008
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of DBC1 were co-immunoprecipitated with AMPK-α1 from cerebellar extracts of HD and WT
samples (Fig 8B). These data suggest two possible scenarios: either the increased interaction of
AMPK-α1 with the SIRT1-DBC1 complex might attempt to promote SIRT1 activation in the
striatum of HD mice through the dissociation from DBC1, or the inability to induce SIRT1 in
R6/2 mice might be due to an inhibitory retention of AMPK-α1 via DBC1.
To gain insight into the molecular events involved in this process we examined the cellular
distribution of AMPK-α1 and DBC1 in the striatum and cerebellum of R6/2 and WTmice at 9
and 14 weeks of age. Consistent with the phenotypes described so far, the distributions AMPK-
α1 and DBC1 were different in the striatum and cerebellum. Interestingly, using western blots
of nuclear and cytoplasmic fractions, we were able to detect DBC1 in both cellular compart-
ments and, although at 9 weeks of age DBC1 was slightly more abundant in the striatal cyto-
plasmic fraction, this balance was reverted by 14 weeks of age for both R6/2 and WTmice (Fig
8C). In contrast cerebellar DBC1 remained constant between the two cellular compartments at
9 and 14 weeks of age for both R6/2 and WTmice (Fig 8D). We next monitored the distribu-
tion of AMPK-α1 by immunostaining nuclei isolated from the striata of R6/2 and WTmice at
4, 9 and 14 weeks of age. At 9 weeks, AMPK-α1 was present in the nuclei from the WT stria-
tum, whereas it could not be detected in nuclei from the striatum of R6/2 mice until 14 weeks
of age (Fig 8E). Conversely, cerebellar extracts showed an early nuclear accumulation of
AMPK-α1 in R6/2 at 9 weeks of age as compared to WT mice, where AMPK-α1 could only be
detected in the nucleus at 14 weeks of age (Fig 8F). These data were confirmed by western blot
(Fig 8C and 8D). The nuclear accumulation of AMPK-α1 at 9 weeks of age in the striatum of
WT mice, in conjunction with an induction of SIRT1 activity, might indeed support a role for
this kinase in the activation of SIRT1. This mechanism appears to be compromised in R6/2
mice and in this case, AMPK-α1 does not reach the nucleus until 14 weeks. Therefore, the
increased interaction between AMPK-α1 and DBC1 might result in the retention of AMPK-α1
in the cytoplasm inhibiting the activation of SIRT1, and/or attempting to rescue SIRT1 activity
by preventing DBC1 from binding to SIRT1. Conversely, the early nuclear accumulation of
AMPK-α1 in the cerebellum of R6/2 at 9 weeks of age as compared to WT mice with the con-
comitant alteration in SIRT1 function might be an attempt to increase impaired SIRT1 activity.
Taken together these data suggest that the inhibition of SIRT1 function in the striatum of R6/2
might arise through an altered functionality of AMPK-α1 and that AMPK-α1 might be
involved in rescuing a deficient SIRT1 function both in the striatum and cerebellum, although
through different molecular mechanisms.
SIRT1, AMPK-α1 and DBC1 act as partners in the same regulatory
circuit to control SIRT1 activity in the striatum
Our data suggest that AMPK-α1 may play an active role in attempting to rescue SIRT1 defi-
ciency in both the striatum and cerebellum of R6/2 mice. To obtain further evidence for a regu-
latory circuit involving these three proteins, we went on to compare the expression levels of
SIRT1, DBC1 and AMPK-α1 in the striatum and cerebellum of R6/2 at 4, 9 and 14 weeks of
age and HdhQ150 homozygotes at 2 and 22 months as compared to their WT littermates.
Strikingly, there was a synchronised, statistically significant down-regulation (35–40%) of all
three genes at the mRNA level from 4 to 9 weeks of age in the striatum of WT mice (Fig 9A).
We detected the same significant reduction in the striatum of R6/2 mice for Dbc1 and Ampk-
α1, and there was a weak trend for Sirt1 (Fig 9A). Notably, the presence of this regulatory cir-
cuit in the cerebellum was not supported by the same co-ordinated changes in expression lev-
els, although the expression level of Sirt1 was significantly higher in WT mice at 9 and 14
weeks as compared to 4 weeks of age (Fig 9D).
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Fig 9. Expression analysis of SIRT1, DBC1 and AMPK-α1 in R6/2 mice. qPCR analysis of the expression level of Sirt1, Dbc1 and Ampk-α1 in (A) striatum
and (D) cerebellum of R6/2 andWTmice at 4, 9 and 14 weeks of age. Values were calculated relative to 4-weekWTmice. Relative protein level of SIRT1,
DBC1 and AMPK-α1 in (B) striatum and (E) cerebellum of R6/2 andWTmice at 4, 9 and 14 weeks of age. Densitometric values were calculated relatively to
4-weekWTmice. Representative western blots for SIRT1, AMPK-α1 and DBC1 in (C) striatum and (F) cerebellum of R6/2 andWTmice at 4, 9 and 14 weeks
of age. Data are the mean ± SEM. *P<0.05; **P<0.01; ***P<0.001: statistically significant difference as compared to WT at 4 weeks of age. #P<0.05;
###P<0.001: statistically significant difference betweenWT and R6/2. For qPCR n = 8 / genotype; for western blot n = 4 / genotype.
doi:10.1371/journal.pone.0145425.g009
SIRT1 Phosphorylation, Impaired Activity and Huntington’s Disease
PLOS ONE | DOI:10.1371/journal.pone.0145425 January 27, 2016 16 / 25
These mRNA changes did not result in concomitant alterations in the levels of the SIRT1,
DBC1, and AMPK-α1 proteins (Fig 9B, 9C, 9E and 9F). The mRNA changes in the striatum
may be the result of a stabilisation of these proteins between 4 and 9 weeks of age. Indeed, the
levels of all three proteins were equivalent at 2 and 22 months in theHdhQ150 homozygotes
andWT mice (S7A and S7B Fig). Interestingly, we observed a significant upregulation of
AMPK-α1 in the striatum of WT mice between 4 and 9 weeks occurring in conjunction with
the increase in SIRT1 activity, neither of which took place in R6/2 mice (Fig 9B and 9C). The
only change that occurred in the cerebellum was a reduction in the level of SIRT1 in both WT
and R6/2 at 14 weeks of age (Fig 9E and 9F).
Dbc1 ablation does not improve HD-related phenotypes
Our data indicate that brain region specific dysregulated cellular processes result in a reduction
in SIRT1 activity in the brains of HDmouse models. We hypothesis that this is related to the
phosphorylation status of SIRT1 and that the AMPK-α1 kinase attempts to rescue SIRT1 func-
tion. As DBC1 is a negative regulator of SIRT1, and Dbc1 knock-out mice are viable and
healthy [19], we elected to use a genetic approach to ablate DBC1 levels in R6/2 mice and inves-
tigate whether the dissociation between SIRT1 and DBC1 could increase SIRT1 activity and
improve HD phenotypes. We crossed R6/2 transgenic mice with Dbc1 heterozygous knock-out
mice (Dbc1+/-) to obtain Dbc1+/-::R6/2 males that were then crossed with Dbc1+/- females to
generate WT, Dbc1+/-,Dbc1-/-, R6/2, Dbc1+/-::R6/2 and Dbc1-/-::R6/2 mice. As predicted, genetic
ablation of Dbc1 resulted in a significant decrease in Dbc1mRNA and DBC1 protein levels, and
we found that this did not alter the expression of SIRT1 (S8A Fig). To confirm that the removal
of DBC1 resulted in an increase in SIRT1 activity, we immunostained nuclei extracted from the
brains of WT, Dbc1-/-, R6/2 and Dbc1-/-::R6/2 mice at 9 weeks of age for SIRT1, P53, AcP53
and DBC1 and counterstained with DAPI. The absence of DBC1 did not affect the level and
nuclear accumulation of SIRT1 and/or P53 (Fig 10A and 10B). As expected, the ablation of
DBC1 in WTmice resulted in an increase in SIRT1 activity as indicated by a significant reduc-
tion (~65%) in the signal intensity for AcP53 in Dbc1-/- as compared to WT mice (Fig 10B).
SIRT1 activity was decreased in R6/2 mice (consistent with Fig 2) and surprisingly the absence
of DBC1 did not ameliorate this impairment (Fig 10). In line with these results, we did not
detect improvements in the onset and progression of specific behavioural HD-related pheno-
types such as body weight, grip strength and rotarod impairment (S8B, S8C and S8D Fig).
Taken together these results suggest that the negative effect of mutant HTT on SIRT1 activity
might be multifactorial and/or operate outside the inhibitory circuit controlled by DBC1.
Discussion
The involvement of SIRT1 in lifespan extension and cellular protection from aggregation-
prone proteins http://jcb.rupress.org/content/190/5/719.full-ref-91 has made it a promising
therapeutic target for neurodegenerative disorders [46–48]. In the context of HD, the manipu-
lation of SIRT1 activity has not generated results that are easy to interpret. On the one hand,
over expression of SIRT1 has been shown to reduce mutant HTT-induced toxicity in HD
mouse models, improving motor function and reducing brain atrophy [25,26]. In contrast to
this, the pharmacological inhibition of SIRT1 has been shown to have beneficial effects in dro-
sophila and mouse models of HD [29] and on the basis of these results, selisistat was assessed
for safety and tolerability in a clinical trial aimed at the development of HD pharmacodynamic
biomarkers [30]. Despite this interest, the integrity of SIRT1 function in HD has not been com-
prehensively investigated. In the present study, we have shown that SIRT1 activity is impaired
in different brain regions from two distinct mouse models of HD and that this is linked to an
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altered SIRT1 phosphorylation status. Furthermore, we provide insights into the temporal tis-
sue-specific regulation of SIRT1 activity in different brain regions fromWTmice.
To monitor SIRT1 activity in the brain, we analysed P53 acetylation by performing immuno-
histochemistry on nuclei isolated from both R6/2 andHdhQ150 mice as compared to their WT
Fig 10. Dbc1 ablation does not ameliorate the impairment in SIRT1 activity in the brains of R6/2 mice. (A) Representative immunofluorescence image
of nuclei extracted from half brain of WT, Dbc1-/-, R6/2 and Dbc1-/-::R6/2 mice at 9 weeks of age immunostained for SIRT1, AcP53, P53 and DBC1 and
counterstained with DAPI. (B) Relative intensity level of SIRT1, AcP53, P53 and DBC1 immunostaining in A. The quantification indicates that the level of
acetylated P53 is lower in Dbc1-/- mice and higher in R6/2 mice as compared to WT, consistent with a respective increase and decrease in SIRT1 activity.
Scale bar: 10 μm. Data are mean ± SEM. ***P<0.001 statistically significant as compared to WT. n = 4 / genotype.
doi:10.1371/journal.pone.0145425.g010
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littermates. We did not detect an alteration in SIRT1 function at the presymptomatic stage in
either model. However, SIRT1 activity was overtly compromised by 9 weeks of age in the R6/2
mice with a comparable impairment at late stage disease in both models. This was not caused by
SIRT1 sequestration into HTT inclusions and we did not detect any variation in either the level
or sub-cellular distribution of SIRT1 between HD andWTmice. We also showed that this
impairment occurred in liver and therefore extends to peripheral tissues. We would not expect
the increase in P53 acetylation to be caused by the HD-related dysregulation of acetyltrans-
ferases as it has been shown that the P53 acetyltransferases: CREB binding protein, P300 and
P300/CBP associated factor, are inhibited with disease progression in HD [49] and would there-
fore be expected to result in a reduction in P53 acetylation, the opposite to that observed in this
study. We were unable to replicate these results using an independent measure of SIRT1 activity
as the commercial kit that we tested was not specific for SIRT1 in mouse brain lysates.
The role of post-translational modifications in the regulation of SIRT1 activity has been the
subject of several studies and phosphorylation has been described as a major control mecha-
nism [41]. It has been shown that kinases such as JNK1 and CK2 can phosphorylate SIRT1
thereby increasing its nuclear deacetylase activity [44,50]. The phosphorylation of SIRT1 by
JNK1 has also been shown to induce SIRT1 ubiquitination and proteasomal degradation [44].
In this study, although we detected an impaired SIRT1 activity in both the striatum and cere-
bellum of HDmice, the phosphorylation level of SIRT1 changed in opposite directions in these
two brain regions, indicative of a tissue-specific SIRT1 regulation. Our further investigations
led us to identify a striatum-specific phosphorylation-dependent induction of SIRT1 activity
with age in WT mice, which does not occur in the cerebellum. Taken together, our findings
suggest that it is the induction of SIRT1 function that is compromised by mutant HTT in the
striatum of HD mice (Fig 11A), whereas in the cerebellum, mutant HTT impairs an already
established SIRT1 activity.
In an attempt to rescue this SIRT1 deficiency, we crossed R6/2 mice with Dbc1-/- mice, as
DBC1 negatively regulates SIRT1 via the direct interaction with its deacetylase domain [19].
Strikingly, despite a significant upregulation of SIRT1 activity in Dbc1-/- mice, the ablation of
DBC1 from R6/2 mice had no effect on the impairment of SIRT1 activity, suggesting that
mutant HTT alters key regulatory events that lie outside the inhibitory circuit controlled by
DBC1. Consistent with this, the absence of DBC1 did not lead to improvements in the onset
and progression of several behavioural HD-related phenotypes.
In contrast to DBC1, AMPK-α1 has been reported to positively regulate the activity of SIRT1
by inducing SIRT1 activation through its dissociation fromDBC1 [20,45]. In addition, there is
evidence to indicate that AMPK-α1 and SIRT1 can regulate each other [21]. Interestingly, our
co-immunoprecipitation experiments revealed an increased interaction between DBC1 and
AMPK-α1 in the striatum of HDmice, which might point to an attempt to rescue SIRT1 func-
tion. On the other hand, the nuclear accumulation of AMPK-α1 is delayed in the striatal nuclei
of R6/2 mice and its retention in the cytoplasm through an interaction with DBC1might impede
SIRT1 activation. In contrast, the nuclear accumulation of AMPK-α1 in the cerebellum of R6/2
mice occurs earlier than inWTmice, indicating that it might be attempting to relieve the SIRT1
inhibition imposed by mutant HTT. In support of the existence of a striatum-specific regulatory
circuit linking these three proteins in the induction of SIRT1 activity, we found that the downre-
gulation of Sirt1, Dbc1 and Ampk-α1 is co-ordinated inWTmice between 4 and 9 weeks of age.
The protein level of AMPK-α1 increases inWTmice during the same time frame, which corre-
lates with the induction of SIRT1 activity, neither of which occurs in R6/2 mice.
We propose a model whereby disease progression leads to an altered SIRT1 phosphoryla-
tion status. As a consequence, the decrease in SIRT1 activity leads to a reduction in the deacety-
lation of P53 and other SIRT1 substrates, modifications that may contribute to neuronal
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Fig 11. Proposedmodel for the striatum-specific regulation of SIRT1 via phosphorylation in WTmice
and for the impairment in SIRT1 activity in HD brain. (A) The change in SIRT1 phosphorylation status in
the striatum of WTmice between 4 and 9 weeks of age induces an increase in SIRT1 activity followed by a
reduction in acetylated P53. The nuclear accumulation of AMPK-α1 in WT striatum at 9 weeks supports a role
for this kinase in the activation of SIRT1 (AMPK-α1 is not the kinase involved in the change in SIRT1
phosphorylation detected here, as the MpM2 antibody only recognises Ser/Thr-Pro residues and AMPK-α1
does not phosphorylate Ser/Thr residues that are followed by proline). AMPK-α1 is present in the nucleus at 9
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dysfunction (Fig 11B). This would be consistent with previous data showing that the ablation
of P53 from an HDmouse model had beneficial consequences [51]. In conclusion, our data
provide two major new findings. First, we have shown that mechanisms controlling the tissue-
specific regulation of SIRT1 activity differ between brain regions, and we have identified a
novel striatum-specific phosphorylation-dependent mechanism of SIRT1 induction in WT
mice. Second, we demonstrate that SIRT1 activity is impaired in two distinct HD mouse mod-
els. Given that SIRT1 plays a central role in metabolism, longevity and neurodegeneration, loss
of SIRT1 activity may contribute significantly to disease progression in HD. These results pro-
vide new insights into the mechanisms that regulate SIRT1 function and may lead to the devel-
opment of new strategies by which SIRT1 can be manipulated for therapeutic benefit.
Supporting Information
S1 ARRIVE Checklist. NC3Rs ARRIVE Guidelines checklist.
(PDF)
S1 Fig. Measurement of SIRT1 activity with the Fluor de Lys assay. Fluorescence signal
obtained after 0, 20, 40 and 60 minute incubations at 37°C. 25 μg of protein from cortical
lysates of WT or Sirt1KOmice and 2U/well of SIRT1-recombinant protein were incubated
with (A) 50, (B) 100 or (C) 200 μM of substrate and with 200 μM of NAD+ and 5 μMTSA.
n = 2 / genotype. AFU = arbitrary fluorescence units.
(TIF)
S2 Fig. SIRT1 activity becomes reduced in HDmouse models. Representative immunofluo-
rescence image of isolated nuclei extracted from (A) half brain and (C) liver from R6/2 mice at
14 weeks of age and (E) liver from 22 month HdhQ150 mice immunostained for SIRT1, P53
and AcP53 and counterstained with DAPI. (B, D, F) Relative intensity levels of SIRT1, p53 and
Acp53 from immunostained nuclei in (A, C, E) respectively. The quantification indicates that
the level of acetylated P53 is higher in the HD models, consistent with a decrease in SIRT1
activity as depicted in Fig 2C. Scale bar, 10 μm. n = 4 / genotype.
(TIF)
S3 Fig. Mouse sequence of SIRT1 indicating residues detected by the MpM2 antibody. Ser-
Pro residues are highlight in yellow and Thr-Pro residues are highlight in green. Notably, all
the phosphorylation sites recognized by the Mpm2 antibody are located in the N-terminal (1-
244aa, purple) and C-terminal (498-737aa, orange) regions. The catalytic domain of SIRT1 is
underlined in blue.
(TIF)
S4 Fig. SIRT1 phosphorylation is altered in HDmouse models.Western blots of SIRT1 and
phosphorylated SIRT1 (MpM2) after SIRT1 immunoprecipitation from cortical lysates of R6/2
mice at 4, 9 and 14 weeks of age compared to WT littermates. IP = immunoprecipitation,
WB = western blotting.
(TIF)
weeks and activates SIRT1 through a mechanism independent of DBC1. The down-regulation of Sirt1, Dbc1
and Ampk-α1 at the mRNA level between 4 and 9 weeks of age is consistent with these three proteins being
partners in the same regulatory circuit. In the context of HD, the marked reduction in SIRT1 phosphorylation
impedes the induction of SIRT1 activity. The greater interaction between AMPK-α1 and DBC1 may result in
the cytoplasmic retention of AMPK-α1, inhibiting the activation of SIRT1, and/or promoting a futile rescue
attempt by preventing DBC1 from binding to SIRT1. (B) The HD pathogenic process leads to an alteration in
the phosphorylation status of SIRT1, resulting in an impairment in SIRT1 activity which modulated the
function of SIRT1 targets that include P53 and may contribute to neuronal dysfunction.
doi:10.1371/journal.pone.0145425.g011
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S5 Fig. The induction of SIRT1 activity is blocked in the striatum. Representative immuno-
fluorescence images of isolated nuclei extracted from the striata of WT and R6/2 mice at 4, 9
and 14 weeks of age immunostained for (A) SIRT1 and (B) P53, and counterstained with
DAPI. The relative intensity levels of SIRT1 and P53 are depicted alongside. Scale bar, 10 μm.
Data are the mean ± SEM. n = 10 / genotype in 2 pools of 5 striata.
(TIF)
S6 Fig. SIRT1 activity is impaired in the cerebellum. Representative immunofluorescence
image of isolated nuclei extracted from the cerebella of WT and R6/2 mice at 4, 9 and 14 weeks
of age immunostained for (A) SIRT1 and (B) P53, and counterstained with DAPI. The relative
intensity levels of SIRT1 and P53 are depicted alongside. Scale bar, 10 μm. Data are the
mean ± SEM. n = 10 / genotype in 2 pools of 5 cerebella.
(TIF)
S7 Fig. Analysis of the expression levels of SIRT1, DBC1 and AMPK-α1 inHdhQ150
homozygous mice. (A) Relative protein levels and (B) representative western blots of SIRT1,
DBC1 and AMPK-α1 in striatum and cerebellum of 2 and 22-monthHdhQ150 homozygotes
andWT mice. Densitometric values were calculated relative to 2-month WTmice. Data are
mean ± SEM.Hdh = HdhQ150 homozygotes. n = 4 / genotype.
(TIF)
S8 Fig. Dbc1 ablation does not delay the onset and progression of HD phenotypes. (A)
Analysis of DBC1 and SIRT1 expression in 4-week cortex of WT, Dbc1+/- and Dbc1-/- mice. (B)
Body weight, (C) forelimb grip strength and (D) latency to fall from the rotarod were measured
from 4 to 14 weeks of age. Number of mice: WT: 22 (7M-15F), Dbc1+/-: 19 (11M-8F), Dbc1-/-:
18 (9M-9F), R6/2: 22 (13M-9F), Dbc1+/-::R6/2: 18 (9M-9F), Dbc1-/-::R6/2: 19 (6M-13F). Data
are the mean ± SEM. P<0.001: statistically significant difference as compared to WT.
(TIF)
S1 Table. Summary of the working dilution and application of all antibodies.
(DOCX)
S2 Table. Summary of in-house designed primer and probe sequences for qPCR.
(DOCX)
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